SARC037 and SARC041: NOW RECRUITING FOR PATIENTS

About SARC
Together We Can Change Patient Outcomes
Impact

Team

News

Newsletter

History

Financials
Research
Catalyzing Scientific and Clinical Progress
Active Clinical Trials

Trial Design

Completed Clinical Trials

Publications

Sarcoma Centers

Submit a Concept

Funding Opportunities

Career Development Award

Catalyst Program

Resources

Clinical Data Repository

Imaging Resources

Biospecimen Bank
Meetings
Collaborating to Cure Sarcoma
SARC Meeting at ASCO

SARC Meeting at CTOS

Past Meetings

SASS Conference
Education
Resources for Professionals, Patients and Families
Find a SARC Sarcoma Center

Why Choose a Clinical Trial?

Tumor Board

Soft Tissue Sarcoma Subtypes

Bone Sarcoma Types

SARC Talk Podcast
Partner With Us
Investing in the Future of Sarcoma Research
For Researchers

For Industry

For Patients & Caregivers

Research Advocacy Council

For Donors & Supporters

Sign Up For News
Contact Us
Donate

Home » SARC Centers » Yale Cancer Center / Smilow Cancer Hospital

Yale Cancer Center / Smilow Cancer Hospital

April 30, 2021

Join OUR community

Stay up-to-date on clinical trials and learn from our team of sarcoma experts.

About Sarc

SARC (Sarcoma Alliance for Research through Collaboration) is a U.S.-based 501 (c)(3) non-profit cancer research organization dedicated to the development and support of research for the prevention, treatment, and cure of sarcoma – a cancer of the bone and connective tissues of the body.

Financial Conflict of Interest Policy

SARC
P.O. Box 406
Ann Arbor, Michigan 48106

Phone: 734.930.7600
Fax: 734.930.7557
Email: sarc@sarctrials.org

Stay in touch

Sign up for our monthly SARC newsletter and updates on clinical trials.

First Name

Last Name

Email Address *

Clinician / Researcher
Patient / Caregiver
Other

We respect your privacy and are committed to protecting the confidentiality of those who use our web site or interact with us online. SARC does not share, sell, or exchange any information about visitors, donors, newsletter recipients, nor our constituents with any third party.